10 Worst Performing Biotech Stocks in 2024
Biotechnology stocks are among the most volatile in the market due to their high risk.
Ionis Pharmaceuticals Inc (IONS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | OrbiMed Advisors Samuel Isaly | 2,324,447 | $93,117,347 | -3% | 1.69% |
| 2. | Deep Track Capital David Kroin | 2,200,000 | $88,132,000 | +10% | 2.79% |
| 3. | Marshall Wace LLP Paul Marshall And Ian Wace | 1,920,464 | $76,933,792 | +1009% | 0.09% |
| 4. | Biotechnology Value Fund / BVF Inc Mark Lampert | 1,451,879 | $58,162,273 | -55% | 1.7% |
| 5. | 54,500,000 | $56,547,293 | +9% | 2.91% |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $37.92 | 1,194 | Officer | 33,713 | 2024-11-12 | Filing | |
| $38.05 | 6,630 | Officer, Director | 167,393 | 2024-11-12 | Filing | |
| $37.86 | 13,508 | Director | 32,251 | 2024-11-12 | Filing | |
| $38.31 | 53 | Officer | 157 | 2024-10-16 | Filing | |
| $50.04 | 1,995 | Officer | 87,300 | 2024-02-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 21,520,872 | $1,088,740,914 | 0.08% | |
| 2. | 14,203,481 | $718,554,104 | 0.01% | |
| 3. | 9,057,530 | $458,220,441 | 0.01% | |
| 4. | 8,713,987 | $440,840,602 | 6.74% | |
| 5. | 4,707,480 | $238,151,403 | 0.2% |
News See All
10 Best Genomics Stocks To Buy Right Now
Genomics is the study of genes and how they function.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q3 2024 Earnings Call Transcript
Operator: Good morning and welcome to the Ionis Third Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded.
10 Stocks with Biggest Upside Potential According to Hedge Funds
The US equities saw a strong move after the September jobs report exceeded the economists’ estimates.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q2 2024 Earnings Call Transcript
Operator: Good morning, and welcome to the Ionis Second Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2024 Earnings Call Transcript
Operator: Good morning. And welcome to Ionis' First Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded.
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2023 Earnings Call Transcript
Ionis Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.78. Ionis Pharmaceuticals, Inc.
12 Most Promising Gene Editing Stocks According to Hedge Funds
In this piece, we will take a look at the 12 most promising gene editing stocks according to hedge funds.
5 Best Genomics Stocks To Buy Now
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a gene editing company developing treatments for cancer and immune system diseases.
Billionaire Hedge Funds
